메뉴 건너뛰기




Volumn 155, Issue 2, 2016, Pages 295-302

A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancer

Author keywords

Breast cancer; HER2; Trabectedin; Triple negative

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BRCA1 PROTEIN; BRCA2 PROTEIN; CREATINE KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRABECTEDIN; 1,3 DIOXOLANE DERIVATIVE; ERBB2 PROTEIN, HUMAN; TETRAHYDROISOQUINOLINE DERIVATIVE;

EID: 84955752797     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-015-3675-x     Document Type: Article
Times cited : (14)

References (38)
  • 3
    • 79953307884 scopus 로고    scopus 로고
    • Risk factors for relapse after conservative treatment in T1–T2 breast cancer with one to three positive axillary nodes: results of an observational study
    • COI: 1:STN:280:DC%2BC3MzkvV2kug%3D%3D, PID: 2104804
    • Aristei C, Leonardi C, Stracci F, Palumbo I, Luini A, Viale G, Cristallini EG, Cavaliere A, Orecchia R (2011) Risk factors for relapse after conservative treatment in T1–T2 breast cancer with one to three positive axillary nodes: results of an observational study. Ann Oncol 22(4):842–847. doi:10.1093/annonc/mdq470
    • (2011) Ann Oncol , vol.22 , Issue.4 , pp. 842-847
    • Aristei, C.1    Leonardi, C.2    Stracci, F.3    Palumbo, I.4    Luini, A.5    Viale, G.6    Cristallini, E.G.7    Cavaliere, A.8    Orecchia, R.9
  • 6
    • 0034612344 scopus 로고    scopus 로고
    • Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743
    • COI: 1:CAS:528:DC%2BD3cXktFaiurY%3D, PID: 1084157
    • Minuzzo M, Marchini S, Broggini M, Faircloth G, D’Incalci M, Mantovani R (2000) Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci USA 97(12):6780–6784
    • (2000) Proc Natl Acad Sci USA , vol.97 , Issue.12 , pp. 6780-6784
    • Minuzzo, M.1    Marchini, S.2    Broggini, M.3    Faircloth, G.4    D’Incalci, M.5    Mantovani, R.6
  • 7
    • 0035146702 scopus 로고    scopus 로고
    • Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action
    • COI: 1:CAS:528:DC%2BD3MXntlOntQ%3D%3D, PID: 1116513
    • Erba E, Bergamaschi D, Bassano L, Damia G, Ronzoni S, Faircloth GT, D’Incalci M (2001) Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 37(1):97–105
    • (2001) Eur J Cancer , vol.37 , Issue.1 , pp. 97-105
    • Erba, E.1    Bergamaschi, D.2    Bassano, L.3    Damia, G.4    Ronzoni, S.5    Faircloth, G.T.6    D’Incalci, M.7
  • 8
    • 0037074625 scopus 로고    scopus 로고
    • A 3. (ET743)-DNA complex that both resembles an RNA-DNA hybrid and mimicks zinc finger-induced DNA structural distortions
    • COI: 1:CAS:528:DC%2BD38XlsVGhsQ%3D%3D, PID: 1183189
    • Marco E, Garcia-Nieto R, Mendieta J, Manzanares I, Cuevas C, Gago F (2002) A 3. (ET743)-DNA complex that both resembles an RNA-DNA hybrid and mimicks zinc finger-induced DNA structural distortions. J Med Chem 45(4):871–880
    • (2002) J Med Chem , vol.45 , Issue.4 , pp. 871-880
    • Marco, E.1    Garcia-Nieto, R.2    Mendieta, J.3    Manzanares, I.4    Cuevas, C.5    Gago, F.6
  • 9
    • 84955752571 scopus 로고    scopus 로고
    • D’Incalci M, Zambelli A (2015) Trabectedin for the treatment of breast cancer. Expert Opin Investig Drugs (in press
    • D’Incalci M, Zambelli A (2015) Trabectedin for the treatment of breast cancer. Expert Opin Investig Drugs (in press)
  • 10
    • 33745259879 scopus 로고    scopus 로고
    • A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer
    • COI: 1:CAS:528:DC%2BD28XltVOmtLk%3D, PID: 1673602
    • Zelek L, Yovine A, Brain E, Turpin F, Taamma A, Riofrio M, Spielmann M, Jimeno J, Misset JL (2006) A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer 94(11):1610–1614
    • (2006) Br J Cancer , vol.94 , Issue.11 , pp. 1610-1614
    • Zelek, L.1    Yovine, A.2    Brain, E.3    Turpin, F.4    Taamma, A.5    Riofrio, M.6    Spielmann, M.7    Jimeno, J.8    Misset, J.L.9
  • 11
    • 84910646290 scopus 로고    scopus 로고
    • Trabectedin as a single-agent treatment of advanced breast cancer after anthracycline and taxane treatment: a multicenter, randomized, phase II study comparing 2 administration regimens
    • COI: 1:CAS:528:DC%2BC2cXhsV2nsbnE, PID: 2523922
    • Goldstein LJ, Gurtler J, Del Prete SA, Tjulandin S, Semiglazov VF, Bayever E, Michiels B (2014) Trabectedin as a single-agent treatment of advanced breast cancer after anthracycline and taxane treatment: a multicenter, randomized, phase II study comparing 2 administration regimens. Clin Breast Cancer 14(6):396–404. doi:10.1016/j.clbc.2014.06.006
    • (2014) Clin Breast Cancer , vol.14 , Issue.6 , pp. 396-404
    • Goldstein, L.J.1    Gurtler, J.2    Del Prete, S.A.3    Tjulandin, S.4    Semiglazov, V.F.5    Bayever, E.6    Michiels, B.7
  • 13
    • 0035874074 scopus 로고    scopus 로고
    • Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways
    • COI: 1:CAS:528:DC%2BD3MXjs1eitL4%3D, PID: 1130469
    • Damia G, Silvestri S, Carrassa L, Filiberti L, Faircloth GT, Liberi G, Foiani M, D’Incalci M (2001) Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer 92(4):583–588
    • (2001) Int J Cancer , vol.92 , Issue.4 , pp. 583-588
    • Damia, G.1    Silvestri, S.2    Carrassa, L.3    Filiberti, L.4    Faircloth, G.T.5    Liberi, G.6    Foiani, M.7    D’Incalci, M.8
  • 15
    • 84903900546 scopus 로고    scopus 로고
    • Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study
    • COI: 1:STN:280:DC%2BC2crps1Cntw%3D%3D, PID: 2469257
    • Delaloge S, Wolp-Diniz R, Byrski T, Blum JL, Goncalves A, Campone M, Lardelli P, Kahatt C, Nieto A, Cullell-Young M, Lubinski J (2014) Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study. Ann Oncol 25(6):1152–1158. doi:10.1093/annonc/mdu134
    • (2014) Ann Oncol , vol.25 , Issue.6 , pp. 1152-1158
    • Delaloge, S.1    Wolp-Diniz, R.2    Byrski, T.3    Blum, J.L.4    Goncalves, A.5    Campone, M.6    Lardelli, P.7    Kahatt, C.8    Nieto, A.9    Cullell-Young, M.10    Lubinski, J.11
  • 16
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • COI: 1:STN:280:DC%2BD3c7it1Gitg%3D%3D, PID: 1065543
    • Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205–216
    • (2000) J Natl Cancer Inst , vol.92 , Issue.3 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3    Wanders, J.4    Kaplan, R.S.5    Rubinstein, L.6    Verweij, J.7    Van Glabbeke, M.8    van Oosterom, A.T.9    Christian, M.C.10    Gwyther, S.G.11
  • 17
    • 0018687930 scopus 로고
    • A multiple testing procedure for clinical trials
    • PID: 49734
    • O’Brien PC, Fleming TR (1979) A multiple testing procedure for clinical trials. Biometrics 35(3):549–556
    • (1979) Biometrics , vol.35 , Issue.3 , pp. 549-556
    • O’Brien, P.C.1    Fleming, T.R.2
  • 18
    • 70449529019 scopus 로고
    • Discrete sequential boundaries for clinical trials
    • Lan KKG, DeMets DL (1983) Discrete sequential boundaries for clinical trials. Biometrika 70(3):659–663
    • (1983) Biometrika , vol.70 , Issue.3 , pp. 659-663
    • Lan, K.K.G.1    DeMets, D.L.2
  • 19
    • 34247569300 scopus 로고    scopus 로고
    • Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry
    • PID: 1738771
    • Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109(9):1721–1728. doi:10.1002/cncr.22618
    • (2007) Cancer , vol.109 , Issue.9 , pp. 1721-1728
    • Bauer, K.R.1    Brown, M.2    Cress, R.D.3    Parise, C.A.4    Caggiano, V.5
  • 20
    • 84867859783 scopus 로고    scopus 로고
    • Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network
    • PID: 2254464
    • Lin NU, Vanderplas A, Hughes ME, Theriault RL, Edge SB, Wong YN, Blayney DW, Niland JC, Winer EP, Weeks JC (2012) Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 118(22):5463–5472. doi:10.1002/cncr.27581
    • (2012) Cancer , vol.118 , Issue.22 , pp. 5463-5472
    • Lin, N.U.1    Vanderplas, A.2    Hughes, M.E.3    Theriault, R.L.4    Edge, S.B.5    Wong, Y.N.6    Blayney, D.W.7    Niland, J.C.8    Winer, E.P.9    Weeks, J.C.10
  • 21
    • 77957706438 scopus 로고    scopus 로고
    • The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer
    • PID: 2081481
    • Gabos Z, Thoms J, Ghosh S, Hanson J, Deschenes J, Sabri S, Abdulkarim B (2010) The association between biological subtype and locoregional recurrence in newly diagnosed breast cancer. Breast Cancer Res Treat 124(1):187–194. doi:10.1007/s10549-010-1135-1
    • (2010) Breast Cancer Res Treat , vol.124 , Issue.1 , pp. 187-194
    • Gabos, Z.1    Thoms, J.2    Ghosh, S.3    Hanson, J.4    Deschenes, J.5    Sabri, S.6    Abdulkarim, B.7
  • 22
  • 25
    • 84879788003 scopus 로고    scopus 로고
    • Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era
    • PID: 2335256
    • Olson EM, Najita JS, Sohl J, Arnaout A, Burstein HJ, Winer EP, Lin NU (2013) Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast 22(4):525–531. doi:10.1016/j.breast.2012.12.006
    • (2013) Breast , vol.22 , Issue.4 , pp. 525-531
    • Olson, E.M.1    Najita, J.S.2    Sohl, J.3    Arnaout, A.4    Burstein, H.J.5    Winer, E.P.6    Lin, N.U.7
  • 26
    • 84863724882 scopus 로고    scopus 로고
    • Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype
    • PID: 2214707
    • Lowery AJ, Kell MR, Glynn RW, Kerin MJ, Sweeney KJ (2012) Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Res Treat 133(3):831–841. doi:10.1007/s10549-011-1891-6
    • (2012) Breast Cancer Res Treat , vol.133 , Issue.3 , pp. 831-841
    • Lowery, A.J.1    Kell, M.R.2    Glynn, R.W.3    Kerin, M.J.4    Sweeney, K.J.5
  • 28
    • 84923205214 scopus 로고    scopus 로고
    • Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane
    • COI: 1:CAS:528:DC%2BC2MXktlCntrc%3D, PID: 2560586
    • Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Velikova G, Olivo MS, He Y, Dutcus CE, Cortes J (2015) Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 33(6):594–601. doi:10.1200/JCO.2013.52.4892
    • (2015) J Clin Oncol , vol.33 , Issue.6 , pp. 594-601
    • Kaufman, P.A.1    Awada, A.2    Twelves, C.3    Yelle, L.4    Perez, E.A.5    Velikova, G.6    Olivo, M.S.7    He, Y.8    Dutcus, C.E.9    Cortes, J.10
  • 31
    • 84864066561 scopus 로고    scopus 로고
    • Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study
    • COI: 1:CAS:528:DC%2BC38Xht1ygsr7N, PID: 2268980
    • Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, Ellis C, Florance A, Vukelja S, Bischoff J, Baselga J, O’Shaughnessy J (2012) Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 30(21):2585–2592. doi:10.1200/JCO.2011.35.6725
    • (2012) J Clin Oncol , vol.30 , Issue.21 , pp. 2585-2592
    • Blackwell, K.L.1    Burstein, H.J.2    Storniolo, A.M.3    Rugo, H.S.4    Sledge, G.5    Aktan, G.6    Ellis, C.7    Florance, A.8    Vukelja, S.9    Bischoff, J.10    Baselga, J.11    O’Shaughnessy, J.12
  • 33
    • 46749092063 scopus 로고    scopus 로고
    • Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma
    • PID: 1851878
    • Schoffski P, Dumez H, Wolter P, Stefan C, Wozniak A, Jimeno J, Van Oosterom AT (2008) Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma. Expert Opin Pharmacother 9(9):1609–1618. doi:10.1517/14656566.9.9.1609
    • (2008) Expert Opin Pharmacother , vol.9 , Issue.9 , pp. 1609-1618
    • Schoffski, P.1    Dumez, H.2    Wolter, P.3    Stefan, C.4    Wozniak, A.5    Jimeno, J.6    Van Oosterom, A.T.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.